Get the Stockscreener App
300.53
0.54%
-1.62
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Ligand Pharmaceuticals Inc stock is traded at $300.53, with a volume of 264.71K.
It is down -0.54% in the last 24 hours and up +5.48% over the past month.
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.
See More
Previous Close:
$302.15
Open:
$302.72
24h Volume:
264.71K
Relative Volume:
0.79
Market Cap:
$6.02B
Revenue:
$274.48M
Net Income/Loss:
$153.56M
P/E Ratio:
40.75
EPS:
7.3755
Net Cash Flow:
$114.06M
1W Performance:
-0.94%
1M Performance:
+5.48%
6M Performance:
+49.41%
1Y Performance:
+126.25%
1-Day Range:
$297.18
$307.81
1-Week Range:
$293.69
$308.56
52-Week Range:
$129.55
$326.63
Ligand Pharmaceuticals Inc Stock (LGND) Company Profile
Name
Ligand Pharmaceuticals Inc
Sector
Industry
Phone
858-550-7500
Address
3911 SORRENTO VALLEY BLVD, SAN DIEGO, CA
Compare LGND vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LGND
Ligand Pharmaceuticals Inc
|
300.53 | 6.02B | 274.48M | 153.56M | 114.06M | 7.3755 |
VRTX
Vertex Pharmaceuticals Inc
|
477.36 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
656.01 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
918.22 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
189.23 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
271.77 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Ligand Pharmaceuticals Inc Stock (LGND) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-11-26 | Initiated | BofA Securities | Buy |
| Dec-09-25 | Initiated | Citigroup | Buy |
| Apr-10-25 | Initiated | Stifel | Buy |
| Oct-03-24 | Initiated | Oppenheimer | Outperform |
| Jul-30-24 | Initiated | RBC Capital Mkts | Outperform |
| Apr-14-21 | Resumed | Stephens | Overweight |
| Feb-04-21 | Reiterated | H.C. Wainwright | Buy |
| Oct-06-20 | Initiated | Barclays | Overweight |
| Mar-24-20 | Downgrade | Argus | Buy → Hold |
| Mar-10-20 | Initiated | Guggenheim | Neutral |
| Feb-06-20 | Initiated | The Benchmark Company | Buy |
| Sep-19-19 | Upgrade | Barclays | Equal Weight → Overweight |
| Jun-11-19 | Initiated | Barclays | Equal Weight |
| May-03-19 | Reiterated | H.C. Wainwright | Buy |
| Mar-06-19 | Reiterated | H.C. Wainwright | Buy |
| Oct-29-18 | Upgrade | ROTH Capital | Neutral → Buy |
| Oct-02-18 | Reiterated | H.C. Wainwright | Buy |
| Sep-11-18 | Reiterated | Argus | Buy |
| Aug-17-18 | Initiated | Goldman | Neutral |
| Aug-08-18 | Downgrade | ROTH Capital | Buy → Neutral |
| Jun-21-18 | Initiated | Argus | Buy |
| Dec-27-17 | Reiterated | H.C. Wainwright | Buy |
| Sep-05-17 | Resumed | H.C. Wainwright | Buy |
| Oct-05-16 | Reiterated | H.C. Wainwright | Buy |
| Aug-05-16 | Downgrade | Deutsche Bank | Hold → Sell |
| Mar-11-16 | Initiated | Sidoti | Buy |
| Mar-03-16 | Initiated | H.C. Wainwright | Buy |
View All
Ligand Pharmaceuticals Inc Stock (LGND) Latest News
Ligand Pharmaceuticals Incorporated (LGND) stock price, news, quote and history - Yahoo Finance UK
Ligand Pharmaceuticals Incorpor (LGND) Stock Forecasts - Yahoo! Finance Canada
Ligand Pharmaceuticals Incorporated (LGND) Stock Price, News, Quote & History - Yahoo! Finance Canada
Ligand Pharmaceuticals to report Q2 2026 results on August 6 - scanx.trade
Ligand Sets Aug. 6 Webcast for Second-Quarter Results - Stock Titan
Ligand to Report Second Quarter 2026 Financial Results on August 6, 2026 - The Manila Times
BofA Securities Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Maintains Target Price $388 - Moomoo
ETFs Investing in Ligand Pharmaceuticals Incorporated Stocks - TradingView
Citi Initiates Buy Rating on Ligand Pharmaceuticals (LGND) Follo - GuruFocus
LGND Reinstated by Citigroup -- Price Target Announced at $387 - GuruFocus
Ligand (LGND) Receives Buy Rating with $387 Target from Citi - GuruFocus
XOMA (XOMA) removes unsold securities after $200M shelf and merger - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
Price to earnings forward of Ligand Pharmaceuticals Incorporated – OTC:LGNZZ - TradingView
Press Release: Ligand Completes Acquisition of XOMA Royalty, Creating a Portfolio of More Than 200 Biopharmaceutical Royalty Assets - Moomoo
Free float of Ligand Pharmaceuticals Incorporated – OTC:LGNZZ - TradingView
Ligand Pharmaceuticals Inc (LGND) Q3 2024 Earnings ReportResults, Call & Slides - TipRanks
TVTX, LGND Stocks In Spotlight Ahead Of Monday’s FDA Call On Kidney Drug Filspari - Stocktwits
Price to book forward of Ligand Pharmaceuticals Incorporated – OTC:LGNXZ - TradingView
Benchmark Co. Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Raises Target Price to $335 - Moomoo
Price to book forward of Ligand Pharmaceuticals Incorporated – OTC:LGNZZ - TradingView
LIGAND PHARMACEUTICALS INC : BENCHMARK RAISES TARGET PRICE TO $335 FROM $275 - Bitget
Ligand Pharmaceuticals (LGND) Stock Looks Undervalued On Cash Flow Yet Overvalued On Earnings - Yahoo Finance
XOMA Royalty Corp (XOMA) holders tender shares in Ligand merger - Stock Titan
XOMA Royalty Corp (XOMA) investors cashed out at $39 per share in Ligand merger - Stock Titan
Benchmark raises Ligand Pharma stock price target to $335 on XOMA deal - Investing.com Canada
Analysts Are Bullish on These Healthcare Stocks: Boston Scientific (BSX), Ligand Pharma (LGND) - The Globe and Mail
RBC Capital raises Ligand Pharma stock price target on financing By Investing.com - Investing.com Canada
RBC Capital Adjusts Price Target on Ligand Pharmaceuticals to $340 From $262, Maintains Outperform Rating - marketscreener.com
XOMA Royalty Corp (XOMA) director equity converted to $39 cash plus CVRs - Stock Titan
US53220KAJ7 Bond Profile — Key Metrics - TradingView
Ligand Pharmaceuticals Acquires XOMA Royalty for $739M, Doubling Portfolio to 200+ Biopharma Royalty Assets - Minichart
Ligand Pharmaceuticals Closes $739 Million XOMA Royalty Purchase - marketscreener.com
Ligand Pharmaceuticals Amends and Extends $125 Million Revolver to 2028 With Citibank - TradingView
Ligand Pharmaceuticals (Nasdaq: LGND) closes $739M XOMA Royalty acquisition - Stock Titan
XOMA Royalty Announces Closing of Its Acquisition by Ligand - The Manila Times
Ligand completes acquisition of XOMA Royalty for $39 per share By Investing.com - Investing.com Canada
Ligand completes $739M acquisition of XOMA Royalty Corporation By Investing.com - Investing.com Canada
Ligand Completes Acquisition of XOMA Royalty, Creating a Portfolio of More than 200 Biopharmaceutical Royalty Assets - marketscreener.com
Press Release: XOMA Royalty Announces Closing of Its Acquisition by Ligand - Moomoo
XOMA Royalty Corp (XOMA) legal chief’s stock and PSUs converted in Ligand merger - Stock Titan
Travere Therapeutics Wins Much-Awaited Approval For Drug In Rare Kidney Disease - Stocktwits
3 Overlooked Stocks Positioned for the Next Market Rotation - Investing.com
Agenus Inc. announced that it expects to receive $85 million in funding from RA Capital Management, L.P., Ligand Pharmaceuticals Incorporated - marketscreener.com
BofA raises Ligand Pharma stock price target on royalty growth By Investing.com - Investing.com South Africa
Enterprise value to EBITDA forward of Ligand Pharmaceuticals Incorporated – OTC:LGNYZ - TradingView
Enterprise value to EBIT forward of Ligand Pharmaceuticals Incorporated – OTC:LGNYZ - TradingView
Price to book forward of Ligand Pharmaceuticals Incorporated – OTC:LGNYZ - TradingView
Price to earnings forward of Ligand Pharmaceuticals Incorporated – OTC:LGNYZ - TradingView
Ligand Pharmaceuticals Incorporated Stock 12‑Month Price Target Raised to $299.22, Implies 5% Downside - TradingView
LGND Maintained by B of A Securities -- Price Target Raised to $388 - GuruFocus
Ligand Pharmaceuticals Inc Stock (LGND) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.46%
0.84%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):